TH9507 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake in single-use vials |
| Solubility class | Freely soluble in water | Reconstituted with sterile diluent before injection |
| Typical storage temperature | 2 to 8 degrees Celsius | Before reconstitution; protect from light |
| Typical analytical method | Reversed-phase high-performance liquid chromatography | Purity and related-substance testing |
| Identity confirmation | Mass spectrometry | Observed mass near 5.1 kDa for the intact peptide |
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Biological tissue has little inherent contrast in either the light or electron microscope. Staining is employed to give both contrast to the tissue as well as highlighting particular features of interest. When the stain is used to target a specific chemical component of the tissue (and not the general structure), the term histochemistry is used.
== Health concerns == Energy drinks have been associated with health risks, such as masking the effects of intoxication when mixed and consumed with alcohol, and excessive or repeated consumption can lead to cardiac and psychiatric conditions. However, the European Food Safety Authority (EFSA) concluded that an adequate consumption of Monster and other popular energy drinks is safe and that the amount of caffeine in standard Monster cans is unlikely to interact adversely with other typical constituents of energy drinks or with alcohol. Energy drinks have the effects that caffeine and sugar give, but there is no distinct evidence that the wide variety of other ingredients has any effect. In December 2011, 14-year-old Anais Fournier died of "cardiac arrhythmia due to caffeine toxicity" after drinking two 24 US fluid ounces (710 mL) cans of Monster Energy drink containing 240 mg of caffeine per can. Fournier had a pre-existing heart condition, as well as Ehlers–Danlos syndrome. In October 2012, her parents sued the company. Monster Energy has insisted that its energy drink played no role in Fournier's death. A request under the U.S. Freedom of Information Act revealed that from 2003 to 2012 the Food and Drug Administration (FDA) had received reports of five deaths occurring after drinking Monster Energy. The reports did not prove a causal link between the drink and any health problems. In May 2015, the Food Safety and Standards Authority of India (FSSAI) banned the sale of Monster and other energy drinks that contained both caffeine and ginseng.
langsonensis from the Eocene strata from the Na Duong coal mine (Vietnam), and emend the diagnoses of the studied species. Scribano et al. (2026) compare the postcranial anatomy of Libycosaurus bahri and Hexaprotodon garyam from the Miocene strata from Toros-Menalla (Chad), and establish an anatomical framework for the identification of postcranial remains of anthracotheres and hippopotamids. A study on tooth anomalies in specimens of Hippopotamus cf. gorgops from the Olduvai Gorge (Tanzania), interpreted as consistent with traumatic displacement likely linked to aggressive interactions and with reactions to seasonal environmental fluctuations, is published by Fidalgo et al. (2026). Martino et al. (2026) study the cranial phenotypic diversity of hippopotamid material from Ortona (Italy) and related specimens from the Pleistocene of Central and Western Europe, identifying two morphotypes of Hippopotamus antiquus and reporting evidence of significant sexual dimorphism in mandibles of specimens from Maglianella (Italy). Marra (2026) studies morphological variation of Pleistocene hippopotamids from Sicily and Malta, and finds no evidence of presence of additional hippopotamid taxa besides Hippopotamus pentlandi in Sicily. Radović et al. (2026) identify fossil material of a hippopotamus or a related taxon from the Grebci karst area (Bosnia and Herzegovina), representing the first confirmed finding of a member of the genus Hippopotamus in southeastern Europe outside Greece.
Not all enamel layers are visible on the tooth surface because enamel layers that are formed early in crown development are buried by later layers. Hypoplasias on this part of the tooth do not show on the tooth surface. Because of this buried enamel, teeth record stressors from a few months after the start of the event. The proportion of enamel crown formation time represented by this buried enamel varies from up to 50 percent in molars to 15-20 percent in anterior teeth. Surface hypoplasias record stressors occur from about one to seven years, or up to 13 years if the third molar is included.
=== Animal health === Livestock products ($3.4 billion in 2024 revenues) include various medications and vaccines for cattle and poultry. Companion animal products ($2.4 billion in 2024 revenues) include various medications and vaccines for cats, dogs, and horses.
Sources: en.wikipedia.org
=== Perception === Machine perception is the ability to use input from sensors (such as cameras, microphones, wireless signals, active lidar, sonar, radar, and tactile sensors) to deduce aspects of the world. Computer vision is the ability to analyse visual input. The field includes speech recognition, image classification, facial recognition, object recognition, object tracking, and robotic perception.
=== Bone Morphogenetic Protein 1-like proteinases === In a study in 1996, Greenspan's lab showed that Bone Morphogenetic Protein 1 (BMP-1) is a protease responsible for the biosynthetic processing of the precursor protein procollagen I into type I collagen, the most abundant protein in the bodies of vertebrates. The lab also helped define the interactions of BMP1 with morphogens involved in dorsoventral patterning in early embryogenesis. They also were responsible, via various studies, for identifying and characterizing the other mammalian BMP1-like proteinases (BMP1-LPs), showing them to be a small family of proteases that activate and inactivate various growth factors, particularly a subset of the TGFβ superfamily; activate enzymes, such as lysyl oxidase, and biosynthetically process various extracellular structural macromolecules. In fact, the lab provided the preponderance of insights into biological roles of these extracellular proteases that are key to development and homeostasis and to ECM formation, and are important to formation of the cardiovascular system, wound healing, periodontal homeostasis and tooth development, and regulation of nodal Na+ channel clustering in formation of the nodes of Ranvier during neuronal development.
== Properties == Confluentic acid is a member of the class of chemical compounds called depsides. Its IUPAC name is 4-[2-hydroxy-4-methoxy-6-(2-oxoheptyl)benzoyl]oxy-2-methoxy-6-pentylbenzoic acid. The ultraviolet absorbance maxima (λmax) has two peaks at 268 and 304 nm. In the infrared spectrum, significant peaks indicative of the carboxylic acid functional group occur at 1700 cm−1 (C=O stretching in carbonyl groups) and within the broad range of 2600 to 3100 cm−1 (O-H stretching). The broad band at 3100 is due to hydrogen bonding, while the peak at 3500 is the COOH stretching band. Confluentic acid's molecular formula is C28H36O8; it has a molecular mass of 500.57 grams per mole. In its purified form, it exists as crystalline needles with a melting point of 157 °C (315 °F).
Acoustic and seismic metamaterials are also research areas. Metamaterial research is interdisciplinary and involves such fields as electrical engineering, electromagnetics, classical optics, solid state physics, microwave and antenna engineering, optoelectronics, material sciences, nanoscience and semiconductor engineering. Recent developments also suggest potential applications of metamaterials in optical computing, with metamaterial-based systems theoretically being able to perform certain tasks more efficiently than conventional computing.
=== 15 February === A 100-member RSF unit stationed in Al-Muzmum, Sennar State, surrendered to the SAF in Singa after previously fleeing to South Sudan. The SAF claimed to have retaken the El Nour Islamic Complex and the Bahri Thermal Power Plant in Khartoum.
Sources: en.wikipedia.org
== External links == Official website Centers for Medicare and Medicaid Services in the Federal Register Centers for Medicare & Medicaid Services in the Code of Federal Regulations Centers for Medicare & Medicaid Services reports and recommendations from the Government Accountability Office Grants to States for Medicaid account on USAspending.gov Centers for Medicare and Medicaid Innovation account on USAspending.gov State Grants and Demonstration account on USAspending.gov Centers for Medicare and Medicaid Services apportionments on OpenOMB GitHub Repositories GitHub Repositories for Digital Service at CMS
== Symptoms and signs == Symptoms of cardiac amyloidosis are a combination of heart failure and amyloid deposition in various other organs. Amyloid deposition in the heart causes restrictive diastolic heart failure that progresses to systolic heart failure. Cardiac manifestations include:
Nicotinamide adenine dinucleotide kinase 2, mitochondrial (NADK2), is a mitochondrial enzyme encoded by the human NADK2 gene. In eukaryotes it maintains the mitochondrial NADP(H) pool by phosphorylating NAD+ and NADH. NADPH plays a central role in mitochondrial metabolism by providing reducing power for protection against oxidative stress and for mitochondrial fatty acid synthesis (mtFAS), proline biosynthesis, lysine degradation, and the beta oxidation of polyunsaturated fatty acids. NADK2 was identified in humans by Ohashi et al. in 2012, more than a decade after its cytosolic counterpart, NADK1. Mutations in the NADK2 gene cause an autosomal recessive disorder known as NADK2 deficiency.
== Secretion and Regulation == Release of little gastrin I is triggered by the presence of proteins and amino acids in the stomach, gastric distension as well as elevated stomach pH. The release is also promoted by vagal nerve stimulation. Secretion is inhibited by Somatostatin and by acidic gastric pH. This forms a negative feedback loop. Its half-life in circulation is short, around 3-7 minutes, after which it is mainly broken down by the kidneys .
Sources: en.wikipedia.org
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.
The primary measure is usually a cross-sectional abdominal scan that separates internal fat from fat just under the skin. Waist circumference and body weight are recorded as secondary measures because they are easy to obtain but do not distinguish the two fat compartments. Hormone and metabolic blood tests are collected alongside the imaging.
Available follow-up data indicate that visceral fat drifts back toward pretreatment levels once injections stop. The change is therefore best described as treatment-dependent rather than permanent. Investigators continue to debate whether intermittent or repeated courses would preserve any benefit.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.